The Spectrum of Kit (CD117) Immunoreactivity in Lung and Pleural Tumors: A Study of 96 Cases Using a Single-Source Antibody With a Review of the Literature
2004; American Medical Association; Volume: 128; Issue: 5 Linguagem: Inglês
10.1043/1543-2165(2004)128 2.0.co;2
ISSN1543-2165
AutoresKelly J. Butnor, James L. Burchette, Thomas A. Sporn, Samuel P. Hammar, Victor L. Roggli,
Tópico(s)Peptidase Inhibition and Analysis
ResumoAbstract Context.—The development of successful chemotherapeutic agents directed against the Kit receptor tyrosine kinase protein has generated intense interest in the Kit (CD117) immunoreactivity of various neoplasms. Immunoreactivity for Kit in small cell lung carcinoma (SCLC) has been well established. However, data on Kit immunostaining in other lung tumors is limited. Likewise, while solitary fibrous tumors of the gastrointestinal tract have been examined for Kit expression, the Kit staining characteristics of their counterpart in the pleura, namely, localized fibrous tumor, are not well known. Objective.—To characterize the Kit immunohistochemical profiles of major types of lung and pleural tumors. Design.—We stained 60 lung carcinomas, including 11 SCLCs, 4 large cell neuroendocrine carcinomas, 22 squamous cell carcinomas, 23 adenocarcinomas, 11 pulmonary carcinoid tumors, 19 pleural malignant mesotheliomas, and 6 localized pleural fibrous tumors with a commonly used polyclonal Kit antibody. Result...
Referência(s)